Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 1999

View Archived Issues

Fluvastatin induces delayed improvement in coronary flow reserve

BioNumerik initiates phase I clinical trials of promising new anticancer compound

Targeted Genetics: Q4 1998 highlights

AxyS Pharmaceuticals: Q4 1998 highlights

rsIL-4R as a potential treatment for atopic eczema

Transcutaneous nitroglycerin evaluated in controlled trial for MED

Anesta begins launch of novel analgesic

Agents for stimulating upper and lower GI motility in development at Labs. Jacques Logeais

Licensing opportunity from Yeda: vitamin D3 analogue with multiple potential indications

Esteve patents novel compounds with multiple effects on the CNS

New radiolabeled cocaine analogues for diagnostic imaging designed at Emory University

TASP-V, a novel and selective NPY Y2 agonist for rhinitis and asthma

Optically pure trimebutine metabolite useful for chronic pain

Kaneka presents new HSF inhibitors

APA Assay accurately diagnoses patients with fibromyalgia

Rhone-Poulenc Rorer claims series for diabetes and diabetic complications

Angelini studies effects of structural modifications to trazodone on binding profile

AN-207, a targeted cytotoxic compound with potential in treating prostate cancer

TNF-alpha inhibitor discovered at Nisshin Flour Milling as new lead antiinflammatory compound

Microbially produced 5alpha-reductase inhibitor discovered at Snow Brand

Variagenics, Nova Molecular team up to study treatments for neurological diseases

Novel hemostatic cofactors available for licensing from OMRF

New patent strengthens Millennium's position on UCPH

Avanir submits additional efficacy data for docosanol cream to FDA

Corvas presents phase I trial results of novel injectable anticoagulant at ACC meeting

Interim safety results for Flocor in sickle cell patients with acute chest syndrome

OraVax and Peptide Therapeutics merger to be completed early in second quarter

Sustiva recommended for full marketing approval in Europe

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...